ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1596

The Role of Coronary Calcium Screening in Patients with Lupus Who Appear to Be at Low Cardiovascular Risk

Sarah Stoots1, Joshua Baker1 and Joan Von Feldt2, 1University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania, Wilmington, DE

Meeting: ACR Convergence 2022

Keywords: Computed tomography (CT), Heart disease, prevention, Subclinical Cardiovascular Disease, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Abstracts: SLE – Diagnosis, Manifestations, and Outcomes II: Complications

Session Type: Abstract Session

Session Time: 3:00PM-4:30PM

Background/Purpose: Patients with Systemic Lupus Erythematosus (SLE) are at elevated cardiovascular risk. However, common risk calculators such as the atherosclerotic cardiovascular disease (ASCVD) risk estimator that are used to determine whether a patient would benefit from statin therapy (often when ASCVD risk ≥ 7.5%) do not incorporate non-traditional risk factors and may underestimate risk in SLE. Cardiac computed tomography (CT) for quantification of coronary artery calcifications (CAC) has been increasingly utilized as a non-invasive imaging modality to aid cardiovascular risk stratification. Published guidelines recommend statin initiation in patients with abnormal CAC. We aimed to determine how many lupus patients traditionally deemed ‘low risk’ by ASCVD scoring are found to have abnormal CAC and to determine factors associated with CAC in this population. The purpose of this research is to inform clinicians which SLE patients would benefit from CT coronary imaging in order to risk stratify and identify those who should receive statin therapy.

Methods: This is a post-hoc analysis of a prior cohort study.1 Female patients with SLE and matched controls were recruited; clinical and laboratory assessments were conducted, and CT of the coronary arteries was performed. We excluded patients with history of MI, CVA, DM, or LDL ≥190, because cardiology guidelines recommend statin use in these patients. We identified patients with SLE and controls with low ASCVD risk (defined by ASCVD < 7.5%) and determined rates of abnormal CAC within this low-risk category. We used two-sample t-test and two-sample Wilcoxon rank-sum tests in SLE patients with low ASCVD risk to compare various characteristics in those with normal and abnormal calcium scores.

Results: The original study included 165 SLE and 160 age- and sex-matched controls. After excluding those with MI (6), CVA (24), DM (23), or high LDL (11), 129 SLE patients and 141 controls remained. Among the 129 SLE patients, only 6 were high ASCVD risk, and all 6 had abnormal CAC scores (Figure 1). Among 122 SLE at low ASCVD risk, 34/122 (28%) had abnormal CAC (7 with mod-high values). Only 4/34 (12%) of low ASCVD risk with abnormal CAC were taking a statin. Among controls at low ASCVD risk, only 14/129 (11%) had abnormal CAC (none had mod-high values). Among all patients with low ASCVD risk, SLE patients were significantly more likely to have abnormal CAC compared with controls, adjusting for age and race [OR 3.61 (95% CI 1.76, 7.41), p< 0.001]. ASCVD-low risk SLE patients with abnormal CAC were older (47.2 vs 39.7, p=0.0003), with lower GFR (83.6 vs 98.3, p=0.02), longer disease duration (14.3 vs 6.15, p=0.005), higher LDL (117.5 vs 104.2, p=0.04) and total cholesterol (203.7 vs 180.5, p=0.004) compared to patients with normal CAC (Table 1).

Conclusion: Approximately one fourth of SLE patients at low ASVCD risk have abnormal CAC, a substantially higher rate than observed for healthy controls. These data support an approach of screening for CAC in older patients with long-standing SLE even if they are observed to have low ASCVD risk. A low rate of statin use in this population suggests a missed opportunity to improve cardiovascular health through primary prevention.

1Von Feldt JM, et al. Arthritis & Rheumatism 2006

Supporting image 1

Figure 1: Coronary Calcium Scores Amongst SLE Patients and Controls Stratified by ASCVD Risk

Supporting image 2

Table 1: Characteristics of SLE Patients at Low ASCVD Risk with CAC and without CAC


Disclosures: S. Stoots, None; J. Baker, Bristol-Myers Squibb(BMS), RediTrex, Pfizer; J. Von Feldt, None.

To cite this abstract in AMA style:

Stoots S, Baker J, Von Feldt J. The Role of Coronary Calcium Screening in Patients with Lupus Who Appear to Be at Low Cardiovascular Risk [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/the-role-of-coronary-calcium-screening-in-patients-with-lupus-who-appear-to-be-at-low-cardiovascular-risk/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-role-of-coronary-calcium-screening-in-patients-with-lupus-who-appear-to-be-at-low-cardiovascular-risk/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology